Even though Hengrui Pharma has resolved the manufacturing problems cited in a recent FDA complete response letter, a second ...

The three-year initiative is designed to generate 1.9 billion pound sterling ($2.5 billion) in annual cost savings by 2029, against 2.4 billion pound sterling in total one-time costs.  The cost ...

J&J has proposed a $5.5 billion settlement that could resolve roughly 76,000 multi-district litigation and state-level ...

Baxter International has issued a voluntary recall of one lot of cefazolin in dextrose injection after a report that ...

It was another swing and a miss for the biopharma industry on Thursday, when a federal appeals court in Philadelphia unanimously rejected (PDF) a challenge by Novartis on the legality of the Inflation ...

We’ve all been there: a 2:00 a.m. “U Up?” text that wakes you out of a dead sleep. But before hitting send on that reply, Gilead Sciences suggests adding “U Up to Date?” on HIV testing to the ...

Havas Lynx has shaken up the leadership of its New York team, expanding Claire Knapp’s role to cover the office and hiring ...

In a sudden leadership shift, Legend Biotech announced that its CEO Ying Huang, Ph.D., resigned on Friday, with no permanent ...

Even as trial setbacks and pipeline adjustment rear their heads, AstraZeneca feels confident that its core business is on ...

The FDA has approved Otsuka Pharmaceutical’s once-daily extended-release capsule Simtriyo (centanafadine) f | Approval of the ...

Some five months after announcing the planned retirement of its longtime CEO Doug Ingram over what the helmsman dubbed an ...

Roche’s cancer treatment Avastin (bevacizumab) has long been employed as an off-label option for wet age-related macular ...